BioCentury | Mar 28, 2020
Product Development

COVID-19 diagnostic tech tableau

In the ramp-up of testing for COVID-19, two well-established technologies have divided the forefront: RT-PCR and immunoassays. The former tests for active infection by detecting viral RNA, while the latter can be used to detect...
BioCentury | Sep 24, 2019
Clinical News

Helixmith struggling to explain Phase III gene therapy results

...shaved about W1.1 trillion ($981.3 million) from its market cap. Helixmith -- previously known as ViroMed Co. Ltd....
...testing the same therapy to treat diabetic foot ulcers and amyotrophic lateral sclerosis. Paul Bonanos, Associate Editor VM202 ViroMed Co. Ltd. Helixmith...
BioCentury | Mar 9, 2019
Finance

Seventure maps its microbiome future

Seventure Partners' second microbiome-based fund aims to foster a generation of companies beyond those focused only on live therapeutics. On March 5, the firm announced a first close of Health for Life Capital II, intended...
BioCentury | Aug 10, 2018
Company News

Regeneron, bluebird ink multitarget deal for cancer

...other companies in oncology R&D deals: γδ T cell company TC BioPharm Ltd. (Edinburgh, U.K.), ViroMed Co. Ltd....
BioCentury | Aug 6, 2018
Company News

Regeneron, bluebird in multitarget cell therapy deal

...other companies in oncology R&D deals: γδ T cell company TC BioPharm Ltd. (Edinburgh, U.K.), ViroMed Co. Ltd....
BioCentury | Feb 23, 2018
Company News

USAID unveils project to prevent viral pandemics

In a policy paper published in Science , the U.S. Agency for International Development (USAID) and others announced plans to start the Global Virome Project (GVP) which aims to take a pro-active approach to identifying viruses...
BioCentury | Feb 2, 2018
Tools & Techniques

Cutting a new path

...to treat leukodystrophy, spinal muscular atrophy (SMA) and neuropathy from GlaxoSmithKline plc., RegenxBio Inc. and ViroMed Co. Ltd....
...Inc. (NASDAQ:RGNX), Rockville, Md. Sangamo Therapeutics Inc. (NASDAQ:SGMO), Richmond, Calif. University of Florida, Gainesville, Fla. ViroMed Co. Ltd....
BioCentury | Sep 22, 2017
Clinical News

Oncolytics treats first patient in Phase Ib of Reolysin for MM

...OS) Status: Phase Ib started Milestone: Preliminary Phase Ib data (1Q18) Jennie Walters Imnovid lenalidomide pelareorep pomalidomide Reolysin Revlimid VM202 Celgene Corp. Myeloma UK Oncolytics Biotech Inc. ViroMed Co. Ltd....
BioCentury | Aug 24, 2017
Targets & Mechanisms

Rise of the virome

With at least a dozen companies having advanced microbiome-based therapies to the clinic, researchers have started looking beyond bacteria to other types of microbes that inhabit the gut. In Nature Medicine last month, a UCSF...
BioCentury | Aug 9, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Two species of intestinal viruses could help predict the onset of pediatric Type I diabetes. In longitudinal samples of the intestinal viromes of 11 children with serum autoantibodies that are hallmarks of...
Items per page:
1 - 10 of 22
BioCentury | Mar 28, 2020
Product Development

COVID-19 diagnostic tech tableau

In the ramp-up of testing for COVID-19, two well-established technologies have divided the forefront: RT-PCR and immunoassays. The former tests for active infection by detecting viral RNA, while the latter can be used to detect...
BioCentury | Sep 24, 2019
Clinical News

Helixmith struggling to explain Phase III gene therapy results

...shaved about W1.1 trillion ($981.3 million) from its market cap. Helixmith -- previously known as ViroMed Co. Ltd....
...testing the same therapy to treat diabetic foot ulcers and amyotrophic lateral sclerosis. Paul Bonanos, Associate Editor VM202 ViroMed Co. Ltd. Helixmith...
BioCentury | Mar 9, 2019
Finance

Seventure maps its microbiome future

Seventure Partners' second microbiome-based fund aims to foster a generation of companies beyond those focused only on live therapeutics. On March 5, the firm announced a first close of Health for Life Capital II, intended...
BioCentury | Aug 10, 2018
Company News

Regeneron, bluebird ink multitarget deal for cancer

...other companies in oncology R&D deals: γδ T cell company TC BioPharm Ltd. (Edinburgh, U.K.), ViroMed Co. Ltd....
BioCentury | Aug 6, 2018
Company News

Regeneron, bluebird in multitarget cell therapy deal

...other companies in oncology R&D deals: γδ T cell company TC BioPharm Ltd. (Edinburgh, U.K.), ViroMed Co. Ltd....
BioCentury | Feb 23, 2018
Company News

USAID unveils project to prevent viral pandemics

In a policy paper published in Science , the U.S. Agency for International Development (USAID) and others announced plans to start the Global Virome Project (GVP) which aims to take a pro-active approach to identifying viruses...
BioCentury | Feb 2, 2018
Tools & Techniques

Cutting a new path

...to treat leukodystrophy, spinal muscular atrophy (SMA) and neuropathy from GlaxoSmithKline plc., RegenxBio Inc. and ViroMed Co. Ltd....
...Inc. (NASDAQ:RGNX), Rockville, Md. Sangamo Therapeutics Inc. (NASDAQ:SGMO), Richmond, Calif. University of Florida, Gainesville, Fla. ViroMed Co. Ltd....
BioCentury | Sep 22, 2017
Clinical News

Oncolytics treats first patient in Phase Ib of Reolysin for MM

...OS) Status: Phase Ib started Milestone: Preliminary Phase Ib data (1Q18) Jennie Walters Imnovid lenalidomide pelareorep pomalidomide Reolysin Revlimid VM202 Celgene Corp. Myeloma UK Oncolytics Biotech Inc. ViroMed Co. Ltd....
BioCentury | Aug 24, 2017
Targets & Mechanisms

Rise of the virome

With at least a dozen companies having advanced microbiome-based therapies to the clinic, researchers have started looking beyond bacteria to other types of microbes that inhabit the gut. In Nature Medicine last month, a UCSF...
BioCentury | Aug 9, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Two species of intestinal viruses could help predict the onset of pediatric Type I diabetes. In longitudinal samples of the intestinal viromes of 11 children with serum autoantibodies that are hallmarks of...
Items per page:
1 - 10 of 22